
Viking Therapeutics has ridden a powerful multi year share price run, yet the recent pullback and heavier funding needs now put a sharper spotlight on what investors are actually paying for on its balance sheet. With the stock reacting to fresh obesity drug data and capital raises, the open question is how today’s market value lines up against Viking Therapeutics' book value compared with the wider biotech industry.
The stock's next move may depend on whether Viking Therapeutics' current share price still lines up sensibly with its book value when set against the industry average.
If you want to test the same book value question beyond Viking Therapeutics, apply the same rule to a broader set of biotech valuations with 35 high quality undervalued stocks
P/B fits Viking Therapeutics because it is still in a loss making phase and investors are effectively paying for its research pipeline and cash on the balance sheet. The stock trades on a P/B of about 5.6x, well above the broader biotech sector on roughly 1.7x and still below the 7.3x level seen across closer peers.
Because the ratio is far higher than the industry average, the shares screen as overvalued on this simple balance sheet lens, even after the recent pullback around VK2735 updates. Despite the latest Phase 3 progress and fresh obesity data lifting interest in Viking Therapeutics, the current P/B still implies a rich price tag relative to many other biotechs that the market values at lower multiples of book value. Explore the numbers behind Viking Therapeutics's P/B valuation.
Simply Wall St Narratives pick up where the Viking Therapeutics' P/B puzzle leaves off by spelling out what kind of future on growth, profitability and earnings would need to play out for the shares to look materially higher or lower than today’s valuation on the Community page. Rather than leaning on a single multiple or model output, each scenario lays out the assumptions behind its view of value so you can compare those expectations with actual results as they are reported.
One of the top narratives on Viking Therapeutics: 79% undervalued
This Narrative is the bullish analyst Narrative on Simply Wall St, built on the most optimistic analyst price target and forecasts, not one person's view.
"VK2735’s maintenance data, with roughly 16 to 19% weight loss over 21 weeks and high proportions of patients reaching double digit weight loss, opens the door to differentiated labeling and pricing power if long term outcomes align…"
Discover why this Narrative puts Viking Therapeutics at 79% undervalued.
Price tags and book value only tell part of the story for Viking Therapeutics, because separate checks have flagged specific risks that can shift how you weigh everything you just read. Take a closer look at 3 warning signs (1 major) before settling on a valuation.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com